TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. Early in the growth of TESARO we recognized the increasingly critical nature of IT to the growth of the company and determined that we needed to augment our oversight, planning and risk assessment capabilities in that area. We therefore contracted with Daryl Rinaldi, CEO of GizmoFish, LLC and his team to provide these services.
Daryl and the GizmoFish team came up to speed quickly on our business, our vendors and our long-term goals and then become an important liaison between many different parties including company personnel, 3rd party service providers, and IT resource vendors. This co-ordination required translating both technical needs and complex technology solutions into a common, understandable language for all parties.
In addition to driving projects such as periodic IT risk assessments and 3rd party vendor security/compliance assessments, Daryl and the GizmoFish team also provided leadership of, or complementary support for:
Because of his expertise, his pleasant and always respectful communication skills, coupled with his ability to present a concise, prioritized set of action items appropriately assessed for cost vs. benefit, Daryl and his team provided key coverage at that stage of the Company’s development. I would recommend Daryl and the GizmoFish team to other growing biotech and life science firms without reservation.
(Former) Vice President of Finance, TESARO, INC.
TESARO is an oncology-focused pharmaceutical company based in Waltham, MA. Founded in 2010 the company’s first commercial product Varubi that treats chemotherapy-induced nausea and vomiting (CINV) was approved by the FDA in October 2015. In March 2017 TESARO won approval for its drug Zejula to treat ovarian cancer. In December of 2018 TESARO was purchased by GlaxoSmithKline.